Lehmann J, Stöckle M
Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg/Saar.
Urologe A. 2005 Apr;44(4):369-74. doi: 10.1007/s00120-005-0786-8.
Detailed data on treating systemic recurrences of urothelial cancer after radical cystectomy and/or radical upper tract surgery are sparse. This review describes the data available from two large clinical phase III trials, one on systemic chemotherapy for metastatic/inoperable urothelial cancer and the other on adjuvant systemic chemotherapy after radical cystectomy for locally advanced bladder cancer. In addition, an overview of contemporary series on metastasectomy for urothelial cancer with palliative as well as curative intent is presented. The impact of therapeutic options for the treatment of systemic urothelial cancer recurrences such as radiotherapy, surgery or systemic first and second line therapy represented by conventional chemotherapy and contemporary target therapy are discussed.
关于根治性膀胱切除术和/或根治性上尿路手术后尿路上皮癌全身复发治疗的详细数据稀少。本综述描述了两项大型临床III期试验的可用数据,一项是关于转移性/不可切除尿路上皮癌的全身化疗,另一项是关于局部晚期膀胱癌根治性膀胱切除术后的辅助全身化疗。此外,还概述了当代关于以姑息性和治愈性为目的的尿路上皮癌转移灶切除术的系列研究。讨论了放疗、手术或由传统化疗和当代靶向治疗代表的全身一线和二线治疗等治疗选择对全身尿路上皮癌复发治疗的影响。